Firma SIRION BIOTECH, Autor bei PR-Web

SIRION Biotech Achieves ISO-9001:2015 Certification

Posted on 1. March 20222. March 2022 by Firma SIRION BIOTECH Posted in General Tagged becker, biotech, cell, certification, customers, dekra, future, gene, iso, platform, resources, secure, sirion, therapy, with

SIRION Biotech GmbH is proud to announce our achievement of ISO 9001:2015 certification by DEKRA. ISO 9001 is the worlds most widely recognized standard for a quality management system (QMS). It enables companies to operate more effectively on several different […]

Webinar: Developing Lentiviral Vectors for ex vivo and in vivo Gene Therapy

Posted on 26. October 202127. October 2021 by Firma SIRION BIOTECH Posted in General Tagged biotech, car, cassette, cd19, cell, cells, clinical, company, future, gene, process, safety, sirion, vector, webinar

SIRION Biotech, the leading German viral vector company, will present a Webinar on November 17 at 2 PM GMT discussing optimizing lentivirus vector design for improved quality and safety Optimizing the safety of lentiviral vectors has been one of the […]

SIRION Biotech Granted CIR accreditation by French Ministry of Higher Education, Research and Innovation

Posted on 14. October 202114. October 2021 by Firma SIRION BIOTECH Posted in General Tagged biotech, business, cell, crdit, deduct, gene, new, process, research, romain, sirion, therapy, vector, western, with

The French Ministry of Higher Education, Research and Innovation have granted SIRION Biotech a 3-year CIR (Crédit Impôt Recherche) accreditation lasting until end of 2023. As a result, SIRION Biotech GmbH is now on a list of experts accessible on […]

Patient pre-immunization may be bypassed with hAd19a/64 – pre-clinical data look promising

Posted on 7. September 201810. September 2018 by Firma SIRION BIOTECH Posted in General Tagged Ad5, adenovirus, ebola, gene therapy, Genetic medicine, Gentherapie, hAd5, hiv, Immune-oncology, Medical Research, pharma, SIRION Biotech, Vaccination

A recent collaboration between Associate Professor Peter Johannes Holst at University of Copenhagen, his research group and colleagues at Bogor Agricultural University, and Munich based viral vector company SIRION Biotech, demonstrated that their key candidate hAd19a/64 can outperform its counterpart […]

Next-generation AAV gene therapy from joined German forces

Posted on 30. May 2018 by Firma SIRION BIOTECH Posted in Research / Development Tagged aav, adeno-associated virus, crispr, gene delivery, gene therapy, Genetic medicine, Heidelberg University Hospital, Prof. Grimm, SIRION Biotech, viral vectors

The viral vector specialist SIRION Biotech GmbH today announces the signing of a preferred partnership agreement with Heidelberg University Hospital and AAV pioneer Prof. Dirk Grimm. This strategic alliance will enable both partners to offer engineering of novel AAV capsids […]

SIRION Biotech and Vibalogics partner to offer complete Adeno-Associated Virus (AAV) services

Posted on 28. September 201725. May 2018 by Firma SIRION BIOTECH Posted in Research / Development Tagged aav, assay, biotech, clinical, customers, dynamics, gene, new, production, sirion, testing, therapy, vector, vibalogics, virus, with

SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene therapy companies for a start-to-finish Adeno-Associated Virus (AAV) service. The new service offering, which will be available from the beginning of 2018, […]